Research analysts covering SciSparc.
Recent press releases and 8-K filings for SPRC.
SciSparc Subsidiary NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology
SPRC
New Projects/Investments
- SciSparc Ltd.'s majority-owned subsidiary, NeuroThera Labs Inc., which SciSparc holds approximately 75% of, announced on February 2, 2026, that it was granted a U.S. patent for its cannabinoid technology designed to overcome antimicrobial resistance such as MRSA.
- The patented technology combines existing antibiotics with cannabinoids like Δ⁹-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) to enhance their effectiveness against resistant bacterial strains.
- This U.S. patent strengthens NeuroThera's global intellectual property protection, joining previously granted patents for the same technology in the U.S. and Europe.
- The company highlighted the significant market need, noting that MRSA directly caused approximately 130,000 deaths worldwide in 2021, and the global antibiotics market is projected to reach approximately $58 billion in 2026.
5 days ago
SciSparc's NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology
SPRC
Product Launch
New Projects/Investments
- SciSparc's majority-owned subsidiary, NeuroThera Labs Inc., has been granted a U.S. patent for its proprietary combination of antimicrobials and cannabinoids.
- This technology is designed to enhance the efficacy of existing antibiotics against resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA).
- The patent strengthens NeuroThera's global intellectual property protection, joining previously granted patents for the same technology in the U.S. and Europe.
- Pre-clinical studies demonstrated that this synergistic approach can restore the effectiveness of antibiotics against resistant Gram-positive pathogens.
- The global antibiotics market is projected to reach approximately $58 billion in 2026.
5 days ago
SciSparc Completes Acquisition of IP Portfolio for GERD Device
SPRC
M&A
New Projects/Investments
Product Launch
- SciSparc Ltd. has successfully completed the acquisition of an intellectual property portfolio, including the MUSE™ system, an innovative endoscopic device for treating gastroesophageal reflux disease (GERD), from Xylo Technologies Ltd..
- In consideration for the acquired assets, SciSparc issued ordinary shares and pre-funded warrants to Xylo, representing 19.99% of SciSparc's issued and outstanding share capital. Specifically, 1,017,391 pre-funded warrants were issued at an exercise price of $0.001 per share.
- SciSparc intends to commence immediate commercialization of these patented technologies, aiming to replicate Xylo's successful licensing and distribution model, which previously generated $3 million upfront in Greater China, across new territories such as North America, Europe, and Latin America.
- The global GERD device market, which the MUSE™ system targets, was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030.
Jan 26, 2026, 9:01 PM
SciSparc Acquires IP Portfolio for GERD Device Market
SPRC
M&A
New Projects/Investments
Product Launch
- SciSparc has acquired an IP portfolio for innovative endoscopic systems and medical cameras, including the MUSE™ system for treating gastroesophageal reflux disease (GERD), from Xylo Technologies Ltd.
- In consideration for the acquired assets, SciSparc issued ordinary shares and pre-funded warrants to Xylo, representing 19.99% of its issued and outstanding share capital.
- SciSparc intends to immediately commercialize these patented technologies, aiming to replicate Xylo's prior successful licensing and distribution model in Greater China across high-growth territories such as North America, Europe, and Latin America.
- The global GERD device market, which SciSparc intends to target, was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030.
Jan 26, 2026, 1:13 PM
SciSparc Announces Registered Direct Offering
SPRC
- SciSparc Ltd. entered into a securities purchase agreement on January 13, 2026, for a registered direct offering.
- The offering involves the issuance of 766,170 Ordinary Shares at a purchase price of $1.00 per share.
- This offering is expected to generate gross proceeds of approximately $766,170.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
- The closing of the offering is anticipated to occur on or about January 14, 2026.
Jan 13, 2026, 2:01 PM
SciSparc to Acquire Endoscopic System Patents from Xylo Technologies
SPRC
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd.
- The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD).
- In consideration for the acquired assets, SciSparc will issue ordinary shares to Xylo, representing 19.99% of SciSparc's issued and outstanding share capital upon the closing date of March 8, 2026.
- SciSparc intends to commercialize these patented technologies immediately following the transaction closing, aiming to replicate Xylo's successful commercialization model in Greater China (which generated $3 million upfront for Xylo in 2019) across high-growth territories like North America, Europe, and Latin America.
- The global GERD device market, which SciSparc is entering, was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.
Jan 13, 2026, 11:55 AM
SciSparc Receives Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
SPRC
Delisting/Listing Issues
Debt Issuance
- SciSparc Ltd. received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement.
- As of June 30, 2025, the company's stockholders' equity was approximately $(81,000), falling below the Nasdaq minimum of $2,500,000.
- The company has until February 26, 2026, to submit a plan to regain compliance.
- SciSparc expects to demonstrate compliance by December 31, 2025, following the conversion of $4.2 million in debentures and proceeds from a registered direct offering.
Jan 12, 2026, 9:09 PM
SciSparc Announces Nasdaq Minimum Stockholders’ Equity Non-Compliance
SPRC
Delisting/Listing Issues
Debt Issuance
- SciSparc Ltd. (Nasdaq: SPRC) received a notification from Nasdaq for non-compliance with the minimum stockholders' equity requirement of $2,500,000.
- As of June 30, 2025, the company reported stockholders' equity of approximately $(81,000).
- SciSparc has 45 calendar days, until February 26, 2026, to submit a plan to regain compliance, with no immediate effect on its Nasdaq listing.
- The company expects to demonstrate compliance by December 31, 2025, due to proceeds from a $4.2 million debenture conversion in August 2025 and a registered direct offering in November 2025.
Jan 12, 2026, 9:02 PM
SciSparc Subsidiary NeuroThera Labs Granted Patent in Israel
SPRC
New Projects/Investments
- NeuroThera Labs Inc., a subsidiary in which SciSparc holds approximately 75% controlling interest, has been granted a patent by the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines.
- This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues.
- The Israeli patent strengthens global intellectual property protection, joining previously granted patents for the same technology in Europe, Japan, Australia, and Canada.
- Pre-clinical studies showed that NeuroThera's proprietary combination of oxycodone and palmitoylethanolamide (PEA) could prolong analgesic effects and reduce psychoactive adverse events compared to standalone oxycodone, addressing a global oxycodone market valued at approximately $5.5\u2013$5.7 billion in 2024.
Dec 30, 2025, 1:17 PM
SciSparc Ltd. announces registered direct offering
SPRC
- SciSparc Ltd. entered into a securities purchase agreement on November 27, 2025, for a registered direct offering with certain institutional and accredited investors.
- The offering involves the issuance of 1,292,557 Ordinary Shares at a purchase price of $1.75 per share.
- The offering is expected to result in gross proceeds of approximately $2.2 million, with purchasers committing to an aggregate of $2,261,975.
- The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
Nov 28, 2025, 11:10 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more